Trial Profile
A trial to evaluate the relationship between the adverse events and efficacy of sorafenib in patients with metastatic renal cell carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 04 May 2016 New trial record